S.S. Neelapu, F.L. Locke, N.L. Bartlett, L.J. Lekakis, D.B. Miklos, C.A. Jacobson, I. Braunschweig, O.O. Oluwole, T. Siddiqi, Y. Lin, et al., Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377(26), 2531–2544 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S.J. Schuster, M.R. Bishop, C.S. Tam, E.K. Waller, P. Borchmann, J.P. McGuirk, U. Jager, S. Jaglowski, C. Andreadis, J.R. Westin, et al., Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N. Engl. J. Med. 380(1), 45–56 (2019)

Article  CAS  PubMed  Google Scholar 

M. Wang, J. Munoz, A. Goy, F.L. Locke, C.A. Jacobson, B.T. Hill, J.M. Timmerman, H. Holmes, S. Jaglowski, I.W. Flinn, et al., KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382(14), 1331–1342 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J.S. Abramson, M.L. Palomba, L.I. Gordon, M.A. Lunning, M. Wang, J. Arnason, A. Mehta, E. Purev, D.G. Maloney, C. Andreadis, et al., Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254), 839–852 (2020)

Article  PubMed  Google Scholar 

F.L. Locke, A. Ghobadi, C.A. Jacobson, D.B. Miklos, L.J. Lekakis, O.O. Oluwole, Y. Lin, I. Braunschweig, B.T. Hill, J.M. Timmerman, et al., Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20(1), 31–42 (2019)

Article  CAS  PubMed  Google Scholar 

S.J. Schuster, J. Svoboda, E.A. Chong, S.D. Nasta, A.R. Mato, O. Anak, J.L. Brogdon, I. Pruteanu-Malinici, V. Bhoj, D. Landsburg, et al., Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377(26), 2545–2554 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J.N. Brudno, J.N. Kochenderfer, Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15(1), 31–46 (2018)

Article  CAS  PubMed  Google Scholar 

D.H. Yoon, M.J. Osborn, J. Tolar, C.J. Kim, Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T. Int. J. Mol. Sci. 19(2), 340 (2018)

Article  PubMed  PubMed Central  Google Scholar 

N.N. Shah, T.J. Fry, Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16(6), 372–385 (2019)

CAS  PubMed  PubMed Central  Google Scholar 

L. Cherkassky, A. Morello, J. Villena-Vargas, Y. Feng, D.S. Dimitrov, D.R. Jones, M. Sadelain, P.S. Adusumilli, Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126(8), 3130–3144 (2016)

Article  PubMed  PubMed Central  Google Scholar 

M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, J.R. Wunderlich, M.E. Dudley, D.E. White, S.A. Rosenberg, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114(8), 1537–1544 (2009)

Article  CAS  PubMed  PubMed Central  Google Scholar 

T. Shimauchi, K. Kabashima, D. Nakashima, K. Sugita, Y. Yamada, R. Hino, Y. Tokura, Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma. Int. J. Cancer 121(12), 2585–2590 (2007)

Article  CAS  PubMed  Google Scholar 

M.R. Green, S. Rodig, P. Juszczynski, J. Ouyang, P. Sinha, E. O’Donnell, D. Neuberg, M.A. Shipp, Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18(6), 1611–1618 (2012)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Kiyasu, H. Miyoshi, A. Hirata, F. Arakawa, A. Ichikawa, D. Niino, Y. Sugita, Y. Yufu, I. Choi, Y. Abe, et al., Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126(19), 2193–2201 (2015)

Article  CAS  PubMed  PubMed Central  Google Scholar 

P. Armand, S. Rodig, V. Melnichenko, C. Thieblemont, K. Bouabdallah, G. Tumyan, M. Ozcan, S. Portino, L. Fogliatto, M.D. Caballero, et al., Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J. Clin. Oncol. 37(34), 3291–3299 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Ansell, M.E. Gutierrez, M.A. Shipp, D. Gladstone, A. Moskowitz, I. Borello, M. Popa-Mckiver, B. Farsaci, L. Zhu, A.M. Lesokhin, et al., A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (checkmate 039). Blood 128(22), 183–183 (2016)

Article  Google Scholar 

S.M. Ansell, M.C. Minnema, P. Johnson, J.M. Timmerman, P. Armand, M.A. Shipp, S.J. Rodig, A.H. Ligon, M.G.M. Roemer, N. Reddy, et al., Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J. Clin. Oncol. 37(6), 481–489 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S.L. Maude, T.W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M.R. Verneris, H.E. Stefanski, G.D. Myers, et al., Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378(5), 439–448 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J.A. Fraietta, S.F. Lacey, E.J. Orlando, I. Pruteanu-Malinici, M. Gohil, S. Lundh, A.C. Boesteanu, Y. Wang, R.S. O’Connor, W.T. Hwang, et al., Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24(5), 563–571 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

F. Li, Z. Zhang, Y. Xuan, D. Zhang, J. Liu, A. Li, S. Wang, T. Li, X. Shi, Y. Zhang, PD-1 abrogates the prolonged persistence of CD8(+) CAR-T cells with 4-1BB co-stimulation. Signal Transduct. Target Ther. 5(1), 164 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Rafiq, O.O. Yeku, H.J. Jackson, T.J. Purdon, D.G. van Leeuwen, D.J. Drakes, M. Song, M.M. Miele, Z. Li, P. Wang, et al., Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36(9), 847–856 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S.N. Zolov, S.P. Rietberg, C.L. Bonifant, Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. Cytotherapy 20(10), 1259–1266 (2018)

Article  CAS  PubMed  Google Scholar 

E. Hui, J. Cheung, J. Zhu, X. Su, M.J. Taylor, H.A. Wallweber, D.K. Sasmal, J. Huang, J.M. Kim, I. Mellman, et al., T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355(6332), 1428–1433 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

L.B. John, M.H. Kershaw, P.K. Darcy, Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2(10), e26286 (2013)

Article  PubMed  PubMed Central  Google Scholar 

S.L. Maude, G.E. Hucks, A.E. Self, M.K. Talekar, D.T. Teachey, D. Baniewicz, C. Callahan, V. Gonzalez, F. Nazimuddin, M. Gupta, et al., The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). J. Clin. Oncol. 35 (2017)

E.A. Chong, C. Alanio, J. Svoboda, S.D. Nasta, D.J. Landsburg, S.F. Lacey, M. Ruella, S. Bhattacharyya, E.J. Wherry, S.J. Schuster, Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood 139(7), 1026–1038 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

N. Wang, X. Hu, W. Cao, C. Li, Y. Xiao, Y. Cao, C. Gu, S. Zhang, L. Chen, J. Cheng, et al., Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood 135(1), 17–27 (2020)

Article  PubMed  Google Scholar 

B.D. Cheson, R.I. Fisher, S.F. Barrington, F. Cavalli, L.H. Schwartz, E. Zucca, T.A. Lister, A.L. Alliance, Lymphoma G, Eastern Cooperative Oncology G et al., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32(27), 3059–3068 (2014)

Article  Google Scholar 

M. Pennisi, T. Jain, B.D. Santomasso, E. Mead, K. Wudhikarn, M.L. Silverberg, Y. Batlevi, R. Shouval, S.M. Devlin, C. Batlevi, et al., Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 4(4), 676–686 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Lou, C. Chen, X. Long, J. Gu, M. Xiao, D. Wang, X. Zhou, T. Li, Z. Hong, C. Li, et al., Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital PCR versus real-time PCR. J. Mol. Diagn. 22(5), 699–707 (2020)

Article  CAS  PubMed  Google Scholar 

B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235–242 (2002)

Article  CAS  PubMed  Google Scholar 

J.W. Friedberg, Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2011, 498–505 (2011)

Article  PubMed  Google Scholar 

S. Rafiq, R.J. Brentjens, Tumors evading CARs-the chase is on. Nat. Med. 24(10), 1492–1493 (2018)

Article